1.840USD+3.37%Mkt Cap: 77.42M USDP/E: —Last update: 2026-05-26
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug …
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap77.42M USD
Enterprise Value58.78M USD
Revenue (TTM)—
Gross Profit-10.07M USD
Net Income (TTM)-20.16M USD
Revenue/Share—
Last Price1.840 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.93
PEG—
EV/EBITDA-2.99
EV/Revenue—
P/S—
P/B5.30
EPS (TTM)-0.58
EPS (Forward)-0.60
52W Range
1.41015% of range4.340
52W High4.340 USD
52W Low1.410 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-108.60%
ROA-88.35%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-18.47M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-14.37%
Net Debt-15.87M USD
Net Debt/EBITDA0.81
Balance Sheet
Debt/Equity0.04
Current Ratio4.69
Quick Ratio4.32
Book Value/Sh0.3300 USD
Cash/Share0.3880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)7.200 USD
Target Range5.000 USD – 8.000 USD
# Analysts5
Ownership
Shares Out.42.65M
Float41.65M
Insiders2.29%
Institutions19.25%
Short Interest
Short Ratio6.2d
Short % Float8.26%
Short % Out.8.07%
Shares Short3.44M
Short (prev mo.)3.28M
Technical
SMA 501.934 (-4.9%)
SMA 2002.190 (-16.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)549.33K
Avg Vol (10d)538.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—